Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omadacycline - Paratek Pharmaceuticals

Next Previous
Drug Profile

Omadacycline - Paratek Pharmaceuticals

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; NUZYRA; PTK-0796; ZL 2401

Latest Information Update: 28 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University
  • Developer Merck & Co; Paratek Pharmaceuticals; ZAI Lab
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Small molecules; Tetracyclines; Urinary anti-infective agents
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Community-acquired pneumonia; Skin and soft tissue infections
  • Preregistration Anthrax
  • Phase II Cystitis; Nontuberculous mycobacterium infections; Pyelonephritis; Urinary tract infections
  • No development reported Acute sinusitis; Bacterial infections; Plague
  • Discontinued Nosocomial infections

Most Recent Events

  • 28 Jun 2025 No recent reports of development identified for phase-I development in Bacterial-infections(In adolescents, In children) in USA (IV)
  • 17 May 2025 Efficacy and adverse events data from a phase IIb trial in Nontuberculous mycobacterium infections presented at the 121st International Conference of the American Thoracic Society (ATS-2025)
  • 17 May 2025 Adverse events and efficacy data from a phase IIIb trial in Community-acquired pneumonia presented at the 121st International Conference of the American Thoracic Society (ATS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top